{"id":17897,"date":"2026-02-04T21:06:07","date_gmt":"2026-02-04T21:06:07","guid":{"rendered":"https:\/\/readtrends.com\/en\/wegovy-ozempic-novo-revenue-2026\/"},"modified":"2026-02-04T21:06:07","modified_gmt":"2026-02-04T21:06:07","slug":"wegovy-ozempic-novo-revenue-2026","status":"publish","type":"post","link":"https:\/\/readtrends.com\/en\/wegovy-ozempic-novo-revenue-2026\/","title":{"rendered":"Wegovy and Ozempic maker forecasts sharp drop in revenue for 2026 &#8211; The Guardian"},"content":{"rendered":"<article>\n<p>Lead: Novo Nordisk, the Danish maker of Wegovy and Ozempic, warned on 4 February 2026 that full-year revenue will likely decline by 5%\u201313% as US price cuts agreed with the government, rising competition and patent expiries weigh on sales. The company said the guidance follows a strong 2025 in which total sales reached 309 billion Danish kroner and profit before tax rose to 130.5 billion kroner. Novo\u2019s shares plunged 17% on the trading day the forecast was published, wiping out gains for the year and contributing to a near-50% decline over the past 12 months. Chief executive Mike Doustdar described the US pricing pressure as &#8220;unprecedented&#8221; and &#8220;painful,&#8221; while stressing the company expects higher volumes as prices fall.<\/p>\n<ul>\n<li>Forecast: Novo Nordisk projects 2026 sales will fall 5%\u201313% from 2025 levels, after 2025 revenue of 309bn DKK and PBT of 130.5bn DKK.<\/li>\n<li>Price concessions: Novo agreed with the US administration to cut average monthly prices for semaglutide products from more than $1,000 to about $350.<\/li>\n<li>Patent risks: Semaglutide patent expiries in several countries, including India, open the door to generic makers and compounded pharmacy alternatives.<\/li>\n<li>Market reaction: Novo shares dropped 17% on the guidance day and have fallen nearly 50% over the past year; Eli Lilly shares rose 9.5% on their stronger guidance.<\/li>\n<li>Product launch: The oral Wegovy tablet reached about 50,000 US prescriptions per week by late January 2026 after its early-month launch.<\/li>\n<li>Competitive landscape: Eli Lilly\u2019s Mounjaro leads in weight-loss efficacy in trials and aims for much higher 2026 sales ($80bn\u2013$83bn vs $65bn in 2025).<\/li>\n<li>Regional patent protection: Novo retains semaglutide patents in Europe and Japan until 2033 and in the US until 2032, partially insulating key markets.<\/li>\n<\/ul>\n<h2>Background<\/h2>\n<p>For several years Novo Nordisk was the market leader in GLP-1\u2013based obesity and diabetes treatments, driven by injectable semaglutide brands such as Ozempic and Wegovy. Global demand for GLP-1 drugs surged as clinical trials and real-world results demonstrated meaningful weight-loss and glycaemic benefits, producing double-digit revenue growth for major developers. The sector shifted sharply in 2025 as new entrants, notably Eli Lilly with its Mounjaro injection, gained clinical and commercial momentum, prompting investors to reprice winners and laggards. In late 2025 and early 2026 US policy moved to reduce drug prices, with administrations negotiating significant cuts in exchange for access and other concessions. These political, legal and commercial shifts set the stage for the guidance Novo issued in February 2026.<\/p>\n<p>Patent timing is central to the sector\u2019s outlook. Semaglutide \u2014 the active molecule in many of Novo\u2019s flagship medicines \u2014 has staggered protection across jurisdictions: extended in Europe and Japan to 2033 and in the US to 2032, but expiring sooner in some markets such as India. Those earlier expiries permit local manufacturers to produce generic semaglutide versions under domestic rules, while compounded pharmacy formulations have already provided cheaper, unbranded options to some US patients. Simultaneously, oral formulations of GLP-1 drugs have reached the market, lowering barriers to uptake and intensifying price competition across retail and insured channels.<\/p>\n<h2>Main Event<\/h2>\n<p>On 4 February 2026 Novo Nordisk published 2026 guidance stating revenues would likely decline by between 5% and 13% compared with 2025, citing a combination of US price concessions, increased competition and the impact of patent expiries. Management described the US pricing agreement with the federal government as a material cut, reducing month-to-month prices from more than $1,000 to an average of roughly $350 for semaglutide-based therapies. The company framed the move as a strategic trade-off: lower prices now to expand long-term volume and broader access.<\/p>\n<p>Novo also highlighted the strong early uptake of its newly launched oral Wegovy tablet, which reached approximately 50,000 US prescriptions per week by late January 2026. The pill is priced for cash payers between $149 and $299 a month depending on dose, while some insurance-enabled channels \u2014 including Amazon Pharmacy \u2014 have listed lower copays for covered patients. Novo\u2019s finance chief called the pills&#8217; launch a &#8220;fantastic update,&#8221; underlining the product\u2019s role in sustaining market relevance even as injected competitors and generics pressure margins.<\/p>\n<p>Investors reacted sharply. Novo shares fell 17% on the day of the guidance, reversing gains for the year and deepening a near-50% drop over the prior 12 months. In contrast, Eli Lilly reported a rosy outlook: projecting $80bn\u2013$83bn in 2026 sales versus about $65bn in 2025, and saw its stock climb around 9.5% in US trading. The divergence highlights how different product mixes, pipeline timing and regional patent positions are shaping market winners and losers within the GLP-1 wave.<\/p>\n<h2>Analysis &#038; Implications<\/h2>\n<p>Novo\u2019s guidance signals a sector turning point: policy intervention on drug prices now directly affects the top line of high-value biologics. Short-term revenue declines driven by negotiated price cuts are, in management\u2019s framing, an investment in broader access and higher long-term volumes. That trade-off matters because GLP-1s have already shown steep demand elasticity \u2014 lower out-of-pocket costs can materially expand the treated population \u2014 but increased uptake does not immediately offset lost per-unit revenue, especially where payer mix shifts.<\/p>\n<p>Patent expiries outside key markets compound the pressure by enabling lower-cost generics and compounded alternatives. In countries with earlier expiries, manufacturers can undercut branded prices quickly, eroding export and regional sales. Retained exclusivity in Europe, Japan and the US provides some runway for Novo, but even in protected markets price concessions and competitive launches (including oral formulations from several firms) compress margins over time.<\/p>\n<p>Strategically, Novo must manage simultaneous priorities: defend premium franchise economics where patents and brand strength allow, accelerate development of next-generation molecules to regain differentiation, and scale lower-cost distribution to capture volume at new price points. For investors and health systems, the episode underscores how political choices \u2014 such as aggressive US price negotiations \u2014 can reshape profit pools across global pharma.<\/p>\n<h2>Comparison &#038; Data<\/h2>\n<figure>\n<table>\n<thead>\n<tr>\n<th>Company \/ Metric<\/th>\n<th>2025 Reported<\/th>\n<th>2026 Guidance<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>Novo Nordisk<\/td>\n<td>Sales: 309bn DKK; PBT: 130.5bn DKK (2025)<\/td>\n<td>Sales: \u22125% to \u221213% vs 2025<\/td>\n<\/tr>\n<tr>\n<td>Eli Lilly<\/td>\n<td>Sales: $65bn (2025)<\/td>\n<td>Sales: $80bn\u2013$83bn (2026 est.; +45%)<\/td>\n<\/tr>\n<tr>\n<td>GSK (UK)<\/td>\n<td>Sales: \u00a332.7bn (2025)<\/td>\n<td>Sales growth: 3%\u20135% (2026 guidance)<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/figure>\n<p>The table illustrates how Novo\u2019s expected decline contrasts with peers: Lilly projects substantial growth driven by competitive products and pipeline momentum, while GSK anticipates modest single-digit growth in a different portfolio mix. Market reactions reflected these outlooks: Novo shares fell sharply on the guidance day while Lilly\u2019s rose and GSK closed at multiyear highs after investor reassurances.<\/p>\n<h2>Reactions &#038; Quotes<\/h2>\n<p>Company leadership framed the guidance as a defensive measure and a pathway to higher long-term volumes.<\/p>\n<blockquote>\n<p>&#8220;Our 2026 guidance reflects a year of unprecedented pricing pressure,&#8221;<\/p>\n<p><cite>Mike Doustdar, CEO, Novo Nordisk<\/cite><\/p><\/blockquote>\n<p>Equity analysts highlighted the combined impact of policy and competition on investor sentiment.<\/p>\n<blockquote>\n<p>&#8220;Donald Trump\u2019s crusade on drug prices, patent expiration, and competition all had their part to play,&#8221;<\/p>\n<p><cite>Derren Nathan, Head of Equity Research, Hargreaves Lansdown<\/cite><\/p><\/blockquote>\n<p>Finance management emphasized the early commercial success of the oral Wegovy tablet.<\/p>\n<blockquote>\n<p>&#8220;A fantastic update&#8221; on the Wegovy pill launch,<\/p>\n<p><cite>Karsten Knudsen, CFO, Novo Nordisk<\/cite><\/p><\/blockquote>\n<aside>\n<details>\n<summary>Explainer: GLP-1 drugs and semaglutide<\/summary>\n<p>GLP-1 receptor agonists are a class of medicines that mimic the gut hormone glucagon-like peptide-1 to reduce appetite and lower blood sugar. Semaglutide is a leading GLP-1 molecule used in multiple products, including Ozempic (typically for diabetes) and Wegovy (for obesity). Patents protect the molecule and specific formulations; when patents expire in a market, generics or compounded versions can be manufactured under local regulations, often at lower prices. Oral formulations represent a new commercial frontier because they are easier to administer than injectables, broadening potential patient pools and altering pricing dynamics.<\/p>\n<\/details>\n<\/aside>\n<h2>Unconfirmed<\/h2>\n<ul>\n<li>The precise magnitude and timing of volume gains that will offset price cuts remain uncertain and depend on payer uptake and prescribing behaviour.<\/li>\n<li>The extent to which compounded pharmacy formulations will continue to cannibalise branded sales in the US is not fully documented in public data.<\/li>\n<li>Timing and commercial details of rival oral GLP-1 launches, including higher-dose pricing and availability, are subject to regulatory approvals and distribution agreements.<\/li>\n<\/ul>\n<h2>Bottom Line<\/h2>\n<p>Novo Nordisk\u2019s 2026 guidance is a milestone for the GLP-1 market: it signals that political pressure on drug prices, patent timing and intense product competition can combine to reverse years of rapid revenue growth for even the sector\u2019s largest players. Management argues the price concessions will expand access and volumes, but investors must weigh near-term margin compression against a longer-term growth case dependent on new products and geographic patent protections.<\/p>\n<p>For patients and payers, lower prices may increase access to effective obesity and diabetes therapies, but the industry consequences include accelerated generic entry, pricing pressure across classes, and a stronger emphasis on next-generation molecules and differentiated formulations. Watch the next earnings cycles, regulatory approvals for oral competitors and patent litigation outcomes \u2014 each will be pivotal in deciding whether Novo can translate lower prices into a sustainable, higher-volume business.<\/p>\n<h2>Sources<\/h2>\n<ul>\n<li><a href=\"https:\/\/www.theguardian.com\/business\/2026\/feb\/04\/wegovy-ozempic-forecast-revenue-share-price-drop\" target=\"_blank\" rel=\"noopener\">The Guardian<\/a> (news media)<\/li>\n<li><a href=\"https:\/\/www.novonordisk.com\/investors.html\" target=\"_blank\" rel=\"noopener\">Novo Nordisk Investor Relations<\/a> (official company investor information)<\/li>\n<\/ul>\n<\/article>\n","protected":false},"excerpt":{"rendered":"<p>Lead: Novo Nordisk, the Danish maker of Wegovy and Ozempic, warned on 4 February 2026 that full-year revenue will likely decline by 5%\u201313% as US price cuts agreed with the government, rising competition and patent expiries weigh on sales. The company said the guidance follows a strong 2025 in which total sales reached 309 billion &#8230; <a title=\"Wegovy and Ozempic maker forecasts sharp drop in revenue for 2026 &#8211; The Guardian\" class=\"read-more\" href=\"https:\/\/readtrends.com\/en\/wegovy-ozempic-novo-revenue-2026\/\" aria-label=\"Read more about Wegovy and Ozempic maker forecasts sharp drop in revenue for 2026 &#8211; The Guardian\">Read more<\/a><\/p>\n","protected":false},"author":1,"featured_media":17893,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"rank_math_title":"Novo Nordisk warns of 2026 revenue drop \u2014 Insight Daily","rank_math_description":"Novo Nordisk forecasts a 5%\u201313% revenue decline in 2026 as US price cuts, competition and patent expiry hit sales; management says lower prices should boost volumes.","rank_math_focus_keyword":"Novo Nordisk,Wegovy,Ozempic,semaglutide,GLP-1","footnotes":""},"categories":[2],"tags":[],"class_list":["post-17897","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-top-stories"],"_links":{"self":[{"href":"https:\/\/readtrends.com\/en\/wp-json\/wp\/v2\/posts\/17897","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/readtrends.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/readtrends.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/readtrends.com\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/readtrends.com\/en\/wp-json\/wp\/v2\/comments?post=17897"}],"version-history":[{"count":0,"href":"https:\/\/readtrends.com\/en\/wp-json\/wp\/v2\/posts\/17897\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/readtrends.com\/en\/wp-json\/wp\/v2\/media\/17893"}],"wp:attachment":[{"href":"https:\/\/readtrends.com\/en\/wp-json\/wp\/v2\/media?parent=17897"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/readtrends.com\/en\/wp-json\/wp\/v2\/categories?post=17897"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/readtrends.com\/en\/wp-json\/wp\/v2\/tags?post=17897"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}